CytRx Corporation (CYTR) Cut to Strong Sell at ValuEngine
ValuEngine cut shares of CytRx Corporation (NASDAQ:CYTR) from a sell rating to a strong sell rating in a report issued on Friday morning.
CytRx Corporation (CYTR) traded down 2.0904% during trading on Friday, reaching $0.5199. The company’s stock had a trading volume of 1,255,640 shares. The company has a 50-day moving average of $0.62 and a 200 day moving average of $0.55. The firm’s market cap is $86.15 million. CytRx Corporation has a one year low of $0.36 and a one year high of $1.00.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/04/cytrx-corporation-cytr-cut-to-strong-sell-at-valuengine.html.
Large investors have recently bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in shares of CytRx Corporation during the first quarter valued at approximately $102,000. Goldman Sachs Group Inc. grew its holdings in shares of CytRx Corporation by 795.0% during the second quarter. Goldman Sachs Group Inc. now owns 703,465 shares of the biotechnology company’s stock valued at $441,000 after buying an additional 624,863 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of CytRx Corporation by 53.9% during the second quarter. Vanguard Group Inc. now owns 4,823,123 shares of the biotechnology company’s stock valued at $3,024,000 after buying an additional 1,689,874 shares during the last quarter. LMR Partners LLP purchased a new stake in shares of CytRx Corporation during the second quarter valued at approximately $235,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of CytRx Corporation during the first quarter valued at approximately $264,000. Hedge funds and other institutional investors own 7.84% of the company’s stock.
CytRx Corporation Company Profile
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Stock Ratings for CytRx Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx Corporation and related stocks with our FREE daily email newsletter.